Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1273 Vaccine in Healthy Adults
NCT04283461Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (15 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Medically-attended Adverse Events, New-onset Chronic Medical Conditions and 3 more. Started Mar 2020; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04283461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283461.